Evidence map›Paper›PMID 40827895›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Evaluation of COVID-19 and Influenza-like Illness Surveillance Case Definitions in a Prospective Cohort of Healthcare Personnel in Peru.

Denisse Vega Ocasio, Neha N Patel, Eva Leidman, Perrine Marcenac, Joseph Daniel Carreon, Chelsea Iwamoto, Giselle M Soto, Matthew Westercamp, Susan Bollinger, Candice Romero and 10 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Denisse Vega OcasioInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Neha N PatelCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Eva LeidmanCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-4191-5931
Perrine MarcenacInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-6726-6124
Joseph Daniel CarreonInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0009-0004-4197-8723
Chelsea IwamotoInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-1117-0198
Giselle M SotoClinical Trials Unit, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Peru.
Matthew WestercampDivision of Healthcare Quality and Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-4773-8876
Susan BollingerDivision of Healthcare Quality and Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Candice RomeroVysnova Partners, Inc. (assigned to Clinical Trials Unit, NAMRU SOUTH), Alexandria, Virginia, USA.
Maria SilvaClinical Trials Unit, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Peru.
Michael ProutyClinical Trials Unit, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Peru.ORCID 0000-0002-1214-3434
Fernanda C LessaDivision of Healthcare Quality and Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Joan NeyraClinical Trials Unit, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Peru.ORCID 0000-0003-3708-9750
Diana PonceVysnova Partners, Inc. (assigned to Clinical Trials Unit, NAMRU SOUTH), Alexandria, Virginia, USA.
Roger CastilloClinical Trials Unit, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Peru.
Alejandro Llanos-CuentasInfectious Diseases and Tropical Medicine Department, Cayetano Heredia Hospital, Lima, Peru.
Eduardo MatosInfectious Diseases Department, Arzobispo Loayza National Hospital, Lima, Peru.ORCID 0000-0002-3832-1657
Rachel M SmithDivision of Healthcare Quality and Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ashley FowlkesInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-0620-6451

Funding

CDC Interagency 22FED2200053IPDIntramural CDC HHS CC999999US Centers for Disease Control and PreventionUS Naval Medical Research Unit SOUTH
6 · The paper itself

Abstract

backgroundPublic health agencies employ case definitions for influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections to optimize surveillance, monitor disease trends, and inform decision-making, particularly in limited resource settings.

methodsUsing a prospective healthcare personnel cohort in two hospitals in Lima, Peru (July 2022-June 2023), we compared and evaluated the performance of three symptom profiles of three common surveillance case definitions to identify influenza and SARS-CoV-2 infections: influenza-like illness, coronavirus disease 2019-like illness (CLI), and acute respiratory infection. Participants with an acute respiratory illness reported symptom progression twice weekly. Participants self-collected nasal swabs for SARS-CoV-2 and influenza reverse transcription real-time polymerase chain reaction testing. Sensitivity, specificity, and positive and negative predictive values of each case definition were evaluated.

resultsOf 1623 participants enrolled, 1450 illness episodes were reported; 92 (6%) were positive for influenza, 350 (24%) for SARS-CoV-2, and 3 (0.2%) were positive for both. For the four influenza-like illness case definitions evaluated, all yielded low sensitivity for detection of influenza (points estimate range, 23%-35%) and SARS-COV-2 (range, 21%-29%), but high specificity (83%-90% and 86%-92%, respectively). In contrast, the acute respiratory infection and coronavirus disease 2019-like illness definitions both yielded high sensitivity (83%-100%) and low specificity (2%-41%) for detection of both influenza and SARS-CoV-2.

conclusionsThe performance of case definitions was similar for influenza and SARS-CoV-2 supporting the use of the same definitions by surveillance networks. The substantial differences in sensitivity and specificity across the case definitions necessitate surveillance objectives and cost considerations in selecting a case definition fit for purpose.

Indexed as

COVID-19Health PersonnelInfluenza, HumanAdultFemaleHumansMaleMiddle AgedPeruProspective StudiesSARS-CoV-2Sensitivity and SpecificityYoung Adultcase definitionsCOVID-19influenzasurveillance

Identifiers

PMID40827895
PMCPMC12497955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.